Roivant Sciences Ltd. (ROIV)
Nasdaq · Healthcare · Biotechnology
$35.78+0.17%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $25.8B
- 52-week range
- $15.25 – $42.50
- 52-week change
- +121.59%
- EPS (trailing)
- −$0.53
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Mar 2026
- Revenue
- $8.3M (−71.57%)
- Net income
- −$300M
- Operating margin
- −6235.7%
- Diluted EPS
- −$0.54
- Free cash flow
- −$759M
From the company’s annual report on SEC EDGAR.
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
Headquarters: London, United Kingdom · 721 employees · roivant.com